Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

All articles

Showing 49–60 of 411 articles

  • Interpret the evidence

    What three dental nerve cases can tell us about a mixture

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 can refer to a synthetic acetylated seven-amino-acid fragment of thymosin beta-4, although an experimental report needs to identify what its authors used.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Interpret the evidence

    What the four groups in a rat tendon study could compare

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 commonly denotes an acetylated seven-amino-acid fragment of thymosin beta-4. In July 2026, investigators used BPC-157 and a reagent they called TB-500 to ask whether giving them together changed healing after Achilles tendon repair in rats.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Interpret the evidence

    Why collagen appearance and tendon strength can tell different stories

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 generally refers to an acetylated seven-amino-acid fragment of thymosin beta-4. In a 2026 study of rat Achilles tendons, the investigators used BPC-157 and a supplier reagent labeled TB-500.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Understand the science

    Why the exact sequence matters when studying the pair

    BPC-157 is a synthetic 15-amino-acid peptide. The term TB-500 can refer to Ac-LKKTETQ, a synthetic acetylated fragment of the longer molecule thymosin beta-4. The exact sequence matters when scientists compare a study of one ingredient with studies of the two together.

    BPC-157 / TB-5003 sources (2012, 2026)

  • Understand the science

    How the 2026 compounding policy treats single ingredients

    BPC-157 is a synthetic 15-amino-acid peptide, and TB-500 is defined in an October 2026 U.S. policy as an acetylated seven-amino-acid fragment related to thymosin beta-4. The policy gives each substance its own identity and addresses a specific question about compounding under federal law.

    BPC-157 / TB-5002 sources (2026)

  • Interpret the evidence

    What an older knee chart review actually compared

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 usually refers to an acetylated seven-amino-acid fragment of thymosin beta-4. An older 2021 knee report described BPC-157 together with a substance called TB4.

    BPC-157 / TB-5002 sources (2012, 2021)

  • Check methods and identity

    The trials designed to test cagrilintide on its own

    Cagrilintide is an investigational, long-acting peptide that activates receptors for amylin and calcitonin. It is often discussed alongside semaglutide because they are being studied together as CagriSema.

    Cagrilintide3 sources (2025, 2026)

  • Interpret the evidence

    Why REIMAGINE 2 compared cagrilintide with semaglutide

    Cagrilintide is an investigational long-acting peptide modeled on amylin. Semaglutide acts on the GLP-1 receptor. REIMAGINE 2 studied the two peptides alone and together in people with type 2 diabetes and overweight or obesity.

    Cagrilintide2 sources (2025, 2026)

  • Interpret the evidence

    What a cagrilintide combination changed in a basal insulin trial

    Cagrilintide is an investigational peptide designed to act like the hormone amylin for longer. In the 2026 REIMAGINE 3 study, researchers asked what changed when the cagrilintide–semaglutide combination, called CagriSema, was added to basal insulin in adults with type 2 diabetes.

    Cagrilintide1 source (2026)

  • Interpret the evidence

    What the Japan and Taiwan CagriSema trial adds to the evidence

    Cagrilintide is a long-acting investigational amylin-based peptide. CagriSema pairs it with the GLP-1 receptor agonist semaglutide. In REDEFINE 5, researchers examined whether the combination produced a different weight change from semaglutide alone in adults studied in Japan and Taiwan.

    Cagrilintide1 source (2026)

  • Understand the science

    How REDEFINE 1 researchers studied blood pressure

    Cagrilintide is an investigational amylin-based peptide studied alone and as part of CagriSema with semaglutide. An analysis published in December 2025 examined blood pressure readings collected in the REDEFINE 1 weight-management trial.

    Cagrilintide3 sources (2023–2026)

  • Explore study findings

    Why the four arms of REDEFINE 1 mattered for cagrilintide

    Cagrilintide is an investigational long-acting amylin-based peptide. The older primary REDEFINE 1 report matters for the specific question of cagrilintide alone because the large weight-management trial included a separate cagrilintide arm alongside the fixed combination.

    Cagrilintide3 sources (2025, 2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)